20 October2014

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Correction: Director Dealing

The following amendments have been made to the Award of Options announcement (RNS Number: 7442U) released at 10.17am on 20 October 2014 by the Company.

Enrico Vanni holds 12,450,000 Ordinary Shares in the Company representing 1.21% of the issued share capital of the Company.

All other details remain unchanged. The full amended text is shown below:

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Director Dealing

The Company announces that Enrico Vanni, Non-Executive Director of the Company, has today purchased 1,000,000 ordinary shares of 1 penny each in the Company ("Ordinary Shares") at 4.08 pence per Ordinary Share.

Following this transaction, Dr Vanni now holds 12,450,000 Ordinary Shares representing 1.21% of the issued share capital of the Company.

For further information contact:

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.